eMedicine Specialties > Otolaryngology and Facial Plastic Surgery > Reconstructive Surgery

Orbital Decompression for Graves Disease

Author: Michael Mercandetti, MD, MBA, FACS, Consulting Staff, Department of Surgery, Doctors Hospital of Sarasota
Coauthor(s): Adam J Cohen, MD, Consulting Surgeon, Myers Wyse Center for the Eye; Director, Center for Facial Rejuvenation; Andrew Marc Marlowe, MD, Private Practice, Sarasota, Florida; David J Terris, MD, FACS, Porubsky Professor and Chairman, Department of Otolaryngology, Medical College of Georgia; Peter Levin, MD, Associate Clinical Professor, Department of Ophthalmology, Stanford University Medical Center
Contributor Information and Disclosures

Updated: Nov 10, 2008

Introduction

Orbitopathy associated with Graves disease may severely compromise a patient's vision. The condition may cause diplopia, decreased ocular motility, exposure keratitis, optic neuropathy, and poor cosmesis. Surgical management is both an alternative and adjunctive treatment to medical therapy, which most often involves corticosteroids, external beam radiotherapy, or both. Orbital decompression most often involves the removal of the bones that comprise the orbit. Decompression of a lesser nature can be accomplished with the removal of extraconal and intraconal fat. This fat decompression can be combined with bone removal for more extensive decompression.

Various surgical approaches can be used for decompression. Otolaryngologists commonly perform decompression via a transantral approach to the medial and inferior orbital walls. An endoscopic approach to the medial and inferior walls is currently used. Oculoplastic specialists often use a transcutaneous or transconjunctival lower lid approach. Often, the lower lid must be separated from its periosteal attachment and subsequently repaired. Transcaruncular approaches can also be used to access the medial orbital wall.

The lateral wall can be surgically approached in different ways. A team approach that involves the services of an otolaryngologist and oculoplastic specialist is common. If the decompression requires the removal of the frontal bone, the services of a neurosurgeon may be required.

Ultimately, the approach or approaches used are tailored to the severity of the problem and therefore the degree of decompression desired and the anatomy of the patient. These decisions can be influenced by the cosmesis achieved, especially in patients who are undergoing decompressions to improve their appearance. A balanced approach in which the inferior wall and medial wall decompression is combined with lateral decompression may be used.

History of the Procedure

Graves disease, originally called Graves-Basedow disease, was first described as the triad of hyperthyroidism, goiter, and exophthalmos in 1835. Dollinger, who described lateral orbital decompression, initially advocated surgical decompression of the orbit for thyroid ophthalmopathy in 1911. Naffziger described an intracranial approach to orbital decompression in 1930.1 This technique was not widely adopted because of the morbidity associated with the procedure and postoperative intracranial complications (eg, meningitis, transmission of CNS pulsations to the orbit).

Otolaryngologists became involved in orbital decompression in 1936 when Sewall described an external ethmoidectomy approach to decompression of the medial orbital wall. This involvement continued with the development of the Walsh-Ogura technique, presented in 1957, which involved a transantral approach to remove both the medial and inferior orbital walls of the bony orbit.2 The Walsh-Ogura technique became the mainstay of surgical treatment for Graves disease. Although effective decompression can be achieved with this method, the incidence of newly onset postoperative diplopia can be high.

In 1993, Garrity et al monitored 428 patients undergoing orbital decompression for Graves ophthalmopathy and reported a 64% incidence of newly onset postoperative diplopia.3 Although the reported incidence is often lower, newly onset diplopia is a concern for all patients who face orbital decompression. The advent of advanced endoscopic techniques has enabled surgeons to decompress the orbit endoscopically, allowing effective decompression with less morbidity. This is primarily a result of circumventing a gingival incision and a low incidence of cranial nerve V2 hypesthesia. Although an endoscopic approach to the medial and inferior walls can be performed in isolation, a balanced approach, incorporating a lateral decompression with repositioning of the lower lid, can be required.

Problem

Severe ophthalmopathy is an uncommon but problematic manifestation of Graves disease. Only 5-6% of patients with Graves disease develop problems severe enough to warrant surgical decompression on a functional basis. This does not include patients who seek cosmetic decompression.

Approximately half of all patients with Graves hyperthyroidism develop ophthalmopathy. In its most involved forms, the ophthalmopathy can result in severe corneal problems that necessitate decompression. Optic neuropathy due to compression of the optic nerve is another indication for decompression.

Frequency

Graves disease is relatively common; it may occur in people of any age but is most common during the third to fifth decades of life. The female-to-male ratio varies from 4:14 to 2.5-6:15 to 8:1 (wikipedia.com, 2006). The distribution is bimodal, with the peak incidence in the fifth and seventh decades of life.6 Men tend to develop more severe orbitopathy. Manifestations of Graves ophthalmopathy develop in less than 5% of patients with the disease.

Etiology

Orbital findings result from an increase in the volume of orbital tissues secondary to inflammation, edema, and congestion. Most notable are the enlargement of the extraocular muscles secondary to infiltration with inflammatory cells, deposition of immune complexes, and an increase in glycosaminoglycans, particularly hyaluronic acid, which is hydrophilic. In some cases, this is ultimately followed by fibrosis. These alterations are mitigated by circulating antibodies. These autoimmune dysfunctions are considered to be mediated by both humoral and cellular dysfunctions; however, this is debated. Regardless, the processes show a predilection for the orbital tissues, the extraocular muscles, and periorbital structures. Both orbitopathy and thyroid dysfunction are more common in family members of patients who have thyroid-related orbitopathy.

Pathophysiology

Severe cases of ophthalmopathy may be associated with lid edema, chemosis (edema of the conjunctiva), and diminished ocular motility. Eventual sequelae may include corneal exposure with subsequent ulceration, diplopia due to extraocular muscle restriction, or fibrosis and optic nerve compression with resulting visual field deficits, including blindness.

Patients with Graves orbitopathy usually have hyperthyroidism but can have euthyroidism or hypothyroidism. A patient may present with signs of orbitopathy prior to being diagnosed with a thyroid disorder. At some point, 90% of patients with orbitopathy have hyperthyroidism. More than 50% of patients develop orbitopathy after they have had hyperthyroidism. The degree of control of the thyroid disorder does not exactly correlate with the extent of the orbitopathy.

The orbit's inflammatory response to the thyroid dysfunction consists of an increase in both B and T lymphocytes, accompanied by edema. These processes can cause scarring. In addition, fibroblastic activity with the resultant production of collagen and glycosaminoglycans also increases. Increased edema and increases in the thickness of the extraocular muscles and fat cells are also found. Some early fibroblasts convert into fat cells.

If a patient has hyperthyroidism, cigarette smoking increases the incidence and severity of thyroid-related orbitopathy.

The antigens that specifically cause this are unclear.

Presentation

Graves-related exophthalmos usually occurs in adult life. The condition most commonly affects middle-aged women. It is more severe in older men, usually with greater exophthalmos. Ethnic variations in the anatomy of the orbits can be found; therefore, the degree of proptosis with its concomitant problems can vary greatly, regardless of race or gender. A person with a tighter orbit is more at risk for compressive optic neuropathy from the disease process and may not show as much proptosis as a person with a much less tight orbit who is more proptotic but does not as readily experience compressive optic neuropathy.

Patients can present in various stages. Patients with very mild cases may have low-grade orbital inflammation with some orbital discomfort, tearing, and chemosis. Other patients may have mild proptosis with or without lid retraction. Still other patients present with marked inflammation, tremendous discomfort, corneal problems, and/or optic nerve compression. Patients may have diplopia.

In burnt-out Graves orbitopathy, many of the same signs persist, except the inflammation is gone and the eyes and orbits appear quiet. However, the proptosis, lid retraction, and/or diplopia still remain.

Graves orbitopathy is the most common cause of unilateral and bilateral proptosis in adults.

Patients with hyperthyroidism can present with symptoms and signs of hyperstimulation of their sympathetic nervous system. These symptoms and signs include the following: weight loss, sweating, tremulousness, edginess, heart palpitations, an increase in appetite, feeling warm, and feeling "revved up."

The ophthalmic presentation can vary significantly.

  • Retraction of the upper or lower lid (Dalrymple sign) may develop. This is due to hyperstimulation of the sympathetically innervated Mueller muscle in the upper lid and its analog, the inferior tarsal muscle, in the lower lid. When the patient tries to look downward, the upper lid can hold back and lag behind the movement of the globe (von Graefe sign; also termed lid lag).
  • Diplopia may develop.
  • Unilateral or bilateral proptosis (34-93% of patients), tearing (epiphora), chemosis (edema of the conjunctiva), and hyperemia or injection of the conjunctiva (an increase in the size of the blood vessels) may develop.
  • A prominence of the blood vessels that overly the insertion of the rectus muscles may develop.
  • Edema of the lids and of the malar pad areas may develop.
  • Corneal problems may vary from dryness to perforation when a full-thickness opening in the cornea is present.

Indications

Historically, the indications for surgical decompression of the orbit have included exophthalmos accompanied by corneal exposure and disfigurement and increased orbital pressure produced by swelling of extraocular muscles, which can lead to compressive optic neuropathy and visual loss. Recent advances in the techniques for orbital decompression have decreased the morbidity of the procedure, and a need for cosmetic decompressions is also an indication. Emergent decompression can be warranted in the most severe cases of compression and visual loss. However, this situation is usually concomitantly treated with immunosuppressives, most commonly systemic steroids. Radiation therapy can be used in the acute setting in addition to immunosuppressives; this may also be used for patients who are not surgical candidates.

Relevant Anatomy

For the transcutaneous or transconjunctival lower-lid approach, the inferior oblique muscle must be avoided. In fact, with either approach, during a bony decompression, the orbital space is not entered until the bone has been removed. Opening the periorbita earlier can allow the fat to prolapse, interfering with the dissection.

The infraorbital nerve is to be avoided during any dissection to avoid postoperative paresthesia.

Medially, the dissection and bone removal is accomplished but stays below ethmoidal arteries to avoid compromising the anterior or posterior ethmoidal arteries, causing hemorrhages, and to avoid disrupting the cribriform plate.

Posteromedially, care must be exercised when the sphenoid sinus is entered. If the carotid artery is violated, the result can be catastrophic.

Additionally, in more posterior dissections, damaging or resecting the optic nerve must be avoided during the dissection.

The relevant anatomy for endoscopic orbital decompression is similar to that for endoscopic ethmoidectomy and maxillary antrostomy. Specifically, the middle turbinate insertion at the skull base represents the medial limit of dissection, the fovea ethmoidalis is the superior limit, and the lamina papyracea is the lateral limit. The lamina extends from the nasolacrimal system anteriorly to the annulus of Zinn posteriorly. Cranial nerve V2 runs in the maxillary roof and can be dehiscent.

In all cases, the globe must not be unduly pressed on. The amount and duration of pressure must be monitored to avoid inadvertently compressing the ophthalmic artery.

Contraindications

Patients who are unable to undergo a surgical procedure or who are unwilling to accept the potential complications of surgery are not candidates for orbital decompression. Other relative contraindications include history of chronic sinusitis, immunocompromised condition, bleeding disorders, and atretic sinuses.

More on Orbital Decompression for Graves Disease

Overview: Orbital Decompression for Graves Disease
Workup: Orbital Decompression for Graves Disease
Treatment: Orbital Decompression for Graves Disease
Follow-up: Orbital Decompression for Graves Disease
Multimedia: Orbital Decompression for Graves Disease
References

References

  1. Naffziger HC. Progressive exophthalmos following thyroidectomy: its pathology and treatment. Ann Surg. 1931;94:582-586.

  2. Walsh TE, Ogura JH. Transantral orbital decompression for malignant exopthalmos. Laryngoscope. 1957;67:544-549.

  3. Garrity JA, Fatourechi V, Bergstralh EJ, et al. Results of transantral orbital decompression in 428 patients with severe Graves' ophthalmopathy. Am J Ophthalmol. Nov 15 1993;116(5):533-47. [Medline].

  4. Rootman J, Stewart B, Goldberg RA. Orbital Surgery A Conceptual Approach. Philadelphia Pa: Lippincott-Raven Publishers; 1995:353-384.

  5. Ing E, Bednarczuk T. Thyroid Ophthalmopathy. www.emedicine.com. 2005;Ophthalmology.

  6. Phillips PH. Newmann, NJ editor. The Orbit. in Ophthalmology Clinics of North America. 14:1. Philadelphia PA: W.B. Saunders Company; Mar 2001:109-127.

  7. Kennedy DW. Functional endoscopic sinus surgery. Technique. Arch Otolaryngol. Oct 1985;111(10):643-9. [Medline].

  8. Metson R, Dallow RL, Shore JW. Endoscopic orbital decompression. Laryngoscope. Aug 1994;104(8 Pt 1):950-7. [Medline].

  9. Goldberg RA. Advances in surgical rehabilitation in thyroid eye disease. Thyroid. Sep 2008;18(9):989-95. [Medline].

  10. Chang EL, Bernardino CR, Rubin PA. Transcaruncular orbital decompression for management of compressive optic neuropathy in thyroid-related orbitopathy. Plast Reconstr Surg. Sep 2003;112(3):739-47. [Medline].

  11. Trokel S, Kazim M, Moore S. Orbital fat removal. Decompression for Graves orbitopathy. Ophthalmology. May 1993;100(5):674-82. [Medline].

  12. Shepard KG, Levin PS, Terris DJ. Balanced orbital decompression for Graves' ophthalmopathy. Laryngoscope. Nov 1998;108(11 Pt 1):1648-53. [Medline].

  13. Kennedy DW, Goodstein ML, Miller NR, et al. Endoscopic transnasal orbital decompression. Arch Otolaryngol Head Neck Surg. Mar 1990;116(3):275-82. [Medline].

  14. Metson R, Shore JW, Gliklich RE, et al. Endoscopic orbital decompression under local anesthesia. Otolaryngol Head Neck Surg. Dec 1995;113(6):661-7. [Medline].

  15. Ben Simon GJ, Mansury AM, Schwarcz RM, et al. Simultaneous orbital decompression and correction of upper eyelid retraction versus staged procedures in thyroid-related orbitopathy. Ophthalmology. May 2005;112(5):923-32. [Medline].

  16. Baldeschi L, Wakelkamp IM, Lindeboom R, et al. Early versus late orbital decompression in Graves' orbitopathy: a retrospective study in 125 patients. Ophthalmology. May 2006;113(5):874-8. [Medline].

  17. Baldeschi L, MacAndie K, Koetsier E, et al. The influence of previous orbital irradiation on the outcome of rehabilitative decompression surgery in graves orbitopathy. Am J Ophthalmol. Mar 2008;145(3):534-540. [Medline].

  18. Goh MS, McNab AA. Orbital decompression in Graves' orbitopathy: efficacy and safety. Intern Med J. Oct 2005;35(10):586-91. [Medline].

  19. Baldeschi L, Lupetti A, Vu P, et al. Reactivation of Graves' orbitopathy after rehabilitative orbital decompression. Ophthalmology. Jul 2007;114(7):1395-402. [Medline].

  20. Baylis HI, Call NB, Shibata CS. The transantral orbital decompression (Ogura technique) as performed by the ophthalmologist: a series of 24 patients. Ophthalmology. Oct 1980;87(10):1005-12. [Medline].

  21. Bednarczuk T, Kiljanski J, Mrowiec T, et al. T cell interactions with extracellular matrix proteins in patients with thyroid-associated ophthalmopathy. Autoimmunity. 1998;27(4):221-30. [Medline].

  22. Ben Simon GJ, Schwarcz RM, Mansury AM, et al. Minimally invasive orbital decompression: local anesthesia and hand-carved bone. Arch Ophthalmol. Dec 2005;123(12):1671-5. [Medline].

  23. Berke RN. A modified Krönlein operation. Trans Am Ophthalmol Soc. 1953;51:193-231.

  24. DeSanto LW. The total rehabilitation of Graves' ophthalmopathy. Laryngoscope. Oct 1980;90(10 Pt 1):1652-78. [Medline].

  25. Hurwitz JJ, Birt D. An individualized approach to orbital decompression in Graves' orbitopathy. Arch Ophthalmol. May 1985;103(5):660-5. [Medline].

  26. Kasperbauer JL, Hinkley L. Endoscopic orbital decompression for Graves' ophthalmopathy. Am J Rhinol. Nov-Dec 2005;19(6):603-6. [Medline].

  27. Leone CR Jr, Piest KL, Newman RJ. Medial and lateral wall decompression for thyroid ophthalmopathy. Am J Ophthalmol. Aug 15 1989;108(2):160-6. [Medline].

  28. Lyons CJ, Rootman J. Orbital decompression for disfiguring exophthalmos in thyroid orbitopathy. Ophthalmology. Feb 1994;101(2):223-30. [Medline].

  29. Maniglia AJ. Fatal and other major complications of endoscopic sinus surgery. Laryngoscope. Apr 1991;101(4 Pt 1):349-54. [Medline].

  30. Petersen IA, Kriss JP, McDougall IR, et al. Prognostic factors in the radiotherapy of Graves' ophthalmopathy. Int J Radiat Oncol Biol Phys. Aug 1990;19(2):259-64. [Medline].

  31. Seiff SR, Shorr N. Nasolacrimal drainage system obstruction after orbital decompression. Am J Ophthalmol. Aug 15 1988;106(2):204-9. [Medline].

  32. Sewall EC. Operative control of progressive exophthalmos. Arch Otolaryngol Head Neck Surg. 1936;24:621-624.

  33. Shorr N, Neuhaus RW, Baylis HI. Ocular motility problems after orbital decompression for dysthyroid ophthalmopathy. Ophthalmology. Apr 1982;89(4):323-8. [Medline].

  34. Weisman RA, Savino PJ. Management of endocrine orbitopathy. Otolaryngol Clin North Am. Feb 1988;21(1):93-102. [Medline].

  35. Wessler S, Avioli LV. Surgical approach to the ophthalmopathy of Graves' disease. JAMA. Jun 7 1971;216(10):1627-31. [Medline].

  36. Wu CH, Chang TC, Liao SL. Results and predictability of fat-removal orbital decompression for disfiguring graves exophthalmos in an Asian patient population. Am J Ophthalmol. Apr 2008;145(4):755-9. [Medline].

Further Reading

Keywords

Graves disease, orbital decompression, orbital decompression for Graves disease, Grave’s disease, Graves eye disease, Grave disease, Graves' orbitopathy, Graves' ophthalmopathy, endocrine orbitopathy, endocrine ophthalmopathy, endocrine-related proptosis, Graves disease treatment, thyroid ophthalmopathy, thyroid orbitopathy, thyroid-related orbitopathy, thyroid-related ophthalmopathy, thyroid eye disease, thyroid-associated orbitopathy, thyroid-related immune orbitopathy, orbital decompression for Graves' disease, exophthalmos, proptosis, thyroid Graves, thyroid ophthalmopathy

Contributor Information and Disclosures

Author

Michael Mercandetti, MD, MBA, FACS, Consulting Staff, Department of Surgery, Doctors Hospital of Sarasota
Michael Mercandetti, MD, MBA, FACS is a member of the following medical societies: American Academy of Facial Plastic and Reconstructive Surgery, American Academy of Ophthalmology, American College of Surgeons, American Society for Laser Medicine and Surgery, American Society of Ophthalmic Plastic and Reconstructive Surgery, Association of Military Surgeons of the US, and Sarasota County Medical Society
Disclosure: Nothing to disclose.

Coauthor(s)

Adam J Cohen, MD, Consulting Surgeon, Myers Wyse Center for the Eye; Director, Center for Facial Rejuvenation
Adam J Cohen, MD is a member of the following medical societies: American Academy of Ophthalmology and American College of Surgeons
Disclosure: Nothing to disclose.

Andrew Marc Marlowe, MD, Private Practice, Sarasota, Florida
Andrew Marc Marlowe, MD is a member of the following medical societies: American Academy of Otolaryngology-Head and Neck Surgery, American Tinnitus Association, Florida Medical Association, Medical Society of the State of New York, Sarasota County Medical Society, and Vestibular Disorders Association
Disclosure: Nothing to disclose.

David J Terris, MD, FACS, Porubsky Professor and Chairman, Department of Otolaryngology, Medical College of Georgia
David J Terris, MD, FACS is a member of the following medical societies: Alpha Omega Alpha, American Academy of Otolaryngology-Head and Neck Surgery, American Association for the Advancement of Science, American Bronchoesophagological Association, American College of Surgeons, American Head and Neck Society, Federation of American Societies for Experimental Biology, International Association of Endocrine Surgeons, Phi Beta Kappa, Radiation Research Society, Society of University Otolaryngologists-Head and Neck Surgeons, and Triological Society
Disclosure: Nothing to disclose.

Peter Levin, MD, Associate Clinical Professor, Department of Ophthalmology, Stanford University Medical Center
Peter Levin, MD is a member of the following medical societies: American Academy of Ophthalmology and American Society of Ophthalmic Plastic and Reconstructive Surgery
Disclosure: Nothing to disclose.

Medical Editor

Terance (Terry) Ted Tsue, MD, Vice-Chairman for Administrative Affairs, Professor, Residency Program Director, Department of Otolaryngology-Head and Neck Surgery, University of Kansas School of Medicine
Terance (Terry) Ted Tsue, MD is a member of the following medical societies: Alpha Omega Alpha, American Academy of Facial Plastic and Reconstructive Surgery, American Academy of Otolaryngology-Head and Neck Surgery, American College of Surgeons, American Medical Association, American Society for Head and Neck Surgery, Association for Research in Otolaryngology, Johns Hopkins Medical and Surgical Association, Missouri State Medical Association, Phi Beta Kappa, and Society of University Otolaryngologists-Head and Neck Surgeons
Disclosure: Nothing to disclose.

Pharmacy Editor

Francisco Talavera, PharmD, PhD, Senior Pharmacy Editor, eMedicine
Disclosure: Nothing to disclose.

Managing Editor

Stephen G Batuello, MD, Consulting Staff, Colorado ENT Specialists
Stephen G Batuello, MD is a member of the following medical societies: American Academy of Otolaryngology-Head and Neck Surgery, American College of Physician Executives, American Medical Association, and Colorado Medical Society
Disclosure: Nothing to disclose.

CME Editor

Christopher L Slack, MD, Otolaryngology-Facial Plastic Surgery, Private Practice, Associated Coastal ENT; Medical Director, Treasure Coast Sleep Disorders
Christopher L Slack, MD is a member of the following medical societies: Alpha Omega Alpha, American Academy of Facial Plastic and Reconstructive Surgery, American Academy of Otolaryngology-Head and Neck Surgery, and American Medical Association
Disclosure: Nothing to disclose.

Chief Editor

Arlen D Meyers, MD, MBA, Professor, Department of Otolaryngology-Head and Neck Surgery, University of Colorado School of Medicine
Arlen D Meyers, MD, MBA is a member of the following medical societies: American Academy of Facial Plastic and Reconstructive Surgery, American Academy of Otolaryngology-Head and Neck Surgery, and American Head and Neck Society
Disclosure: Covidien Corp Consulting fee Consulting; US Tobacco Corporation unstricted gift unknown

 
 
HONcode

We subscribe to the
HONcode principles of the
Health On the Net Foundation

All material on this website is protected by copyright, Copyright© 1994- by Medscape.
This website also contains material copyrighted by 3rd parties.

DISCLAIMER: The content of this Website is not influenced by sponsors. The site is designed primarily for use by qualified physicians and other medical professionals. The information contained herein should NOT be used as a substitute for the advice of an appropriately qualified and licensed physician or other health care provider. The information provided here is for educational and informational purposes only. In no way should it be considered as offering medical advice. Please check with a physician if you suspect you are ill.